Alex’s Lemonade Stand Foundation Aims to Fast-Track Promises Approaches to Childhood Cancer

It’s common knowledge that there’s a big gap between basic research and the clinical trial stage. That gap is especially problematic for diseases and disorders that are rare, such as glioblastoma multiforme, or some childhood cancers. Some researchers call it the Valley of Death—a grim name, for sure. This crevasse between the lab and the clinic costs lives, as patients simply run out of time waiting for cures stuck in the development pipeline.

To that end, the plucky and inspiring Alex’s Lemonade Stand Foundation is stepping up to accept applications for its 2015 Bio-Therapeutics Impact Award. It’s specifically designed to accelerate the development of clinical trials for promising approaches to childhood cancer, and the pot is huge. The award promises a single grant of $1.5 million over the course of three years.

Gene therapy, immunotherapy, and small molecules are all good prospects, but the grant isn’t limited to researchers working in those fields. The ALSF is simply looking for researchers with a project promising enough to get to the clinical trial phase—and they want to fast track that phase of the process once the project arrives.

To be eligible, researchers must have completed preclinical study for childhood cancer; have a demonstrated track record of implementing novel biologic therapies; and have experience with executing and completing clinical trials and a history of meeting projected accrual targets in a timely manner.

For complete program guidelines and application instructions, visit the Alex's Lemonade Stand Foundation website.